Prenoxad: first opioid antidote for non-clinician use

Martindale has launched Prenoxad (naloxone), the first licensed opioid overdose treatment for use by non-healthcare professionals in the community setting.

Prenoxad is administered intramuscularly into the outer thigh or upper arm and is intended for emergency use in the home or other non-medical setting.
Prenoxad is administered intramuscularly into the outer thigh or upper arm and is intended for emergency use in the home or other non-medical setting.

Supplied in a kit containing a pre-filled syringe and two needles, Prenoxad (naloxone) is licensed for emergency use to reverse life-threatening respiratory depression caused by natural or synthetic opioids. It should be administered by intramuscular injection as part of a resuscitation intervention.

Prenoxad is intended to be carried by individuals at risk of opioid overdose. Prescribers must assess the competence of the patient or representative to administer the product in the appropriate circumstances.

View Prenoxad drug record

Further information: Martindale

Follow MIMS on Twitter


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.